Harpoon Therapeutics Presents HPN217 Interim Phase 1 Data at

Target dose of 12 mg demonstrates robust early activity and manageable tolerability profile:– 63% ORR, 16% cytokine release syndrome , No ICANS – Phase 1 data set, including recommended Phase 2...

Related Keywords

Athens , Attikír , Greece , Luke Walker , Globenewswire Inc , International Myeloma Society , Linkedin , Twitter , Nasdaq , Exchange Commission , Harpoon Therapeutics Inc , Activating Construct , Myeloma Society , Annual Meeting , Chief Medical Officer , Private Securities Litigation Reform Act , Harpoon Therapeutic , Harpoon Therapeutics , Markets ,